CGN Nuclear Technology Development Co., Ltd. (000881.SZ) Latest Company News

Oct 29, 2026, 08:21 UTC
CGN Nuclear Technology Development Co. reported first-three-quarter 2026 revenue of 3.911 billion yuan, down 3.77% year over year, and a net loss attributable to shareholders of 180 million yuan, up 76.57%.
Source:
- finance.sina.cn
Oct 29, 2026, 08:21 UTC
CGN Nuclear Technology Development Co. reported third-quarter 2026 revenue of 1.361 billion yuan, down 7.52% year over year, and a net loss attributable to shareholders of 58.2845 million yuan.
Source:
- finance.sina.cn
Oct 19, 2026, 09:39 UTC
CGN Nuclear Technology announced that Deputy General Manager Wang Xipo resigned due to a work reassignment and would hold no further position at the company.
Source:
- finance.sina.cn
Oct 9, 2026, 04:34 UTC
The Civil Aviation Administration of China granted use licenses to CGN Beigu Technology's BGCT-0824 and BGCT-1050S CT security-screening equipment, qualifying them for checked-baggage screening.
Source:
- finance.sina.cn
Sep 28, 2026, 02:11 UTC
CGN Nuclear Technology Development (000881) wholly invested in and established CGN Molecular Technology (Cangnan) Co., Ltd., a new company engaged in biological reagent R&D and production and sales of heavy oxygen water, ultra-light water and water treatment equipment.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 31, 2026, 07:55 UTC
CGN Nuclear Technology Development Co., Ltd. established a wholly-owned medical technology subsidiary, CGN Hezhi Medical Technology (Shanghai) Co., Ltd., in Shanghai, China, with business scope including medical equipment leasing and sales.
Source:
- finance.sina.cn
Jul 17, 2026, 13:52 UTC
CGN Nuclear Technology signed strategic cooperation agreements on industry-academia-research with Chengdu University of Technology and University of Electronic Science and Technology of China, and jointly inaugurated a particle accelerator laboratory.
Source:
- finance.sina.cn

000881.SZ

CGN Nuclear Technology Development Co. reported first-three-quarter 2026 revenue of 3.911 billion yuan, down 3.77% year over year, and a net loss attributable to shareholders of 180 million yuan, up 76.57%.

CGN Nuclear Technology Development Co. reported third-quarter 2026 revenue of 1.361 billion yuan, down 7.52% year over year, and a net loss attributable to shareholders of 58.2845 million yuan.

CGN Nuclear Technology announced that Deputy General Manager Wang Xipo resigned due to a work reassignment and would hold no further position at the company.

The Civil Aviation Administration of China granted use licenses to CGN Beigu Technology's BGCT-0824 and BGCT-1050S CT security-screening equipment, qualifying them for checked-baggage screening.

CGN Nuclear Technology Development (000881) wholly invested in and established CGN Molecular Technology (Cangnan) Co., Ltd., a new company engaged in biological reagent R&D and production and sales of heavy oxygen water, ultra-light water and water treatment equipment.

CGN Nuclear Technology Development Co., Ltd. established a wholly-owned medical technology subsidiary, CGN Hezhi Medical Technology (Shanghai) Co., Ltd., in Shanghai, China, with business scope including medical equipment leasing and sales.

CGN Nuclear Technology signed strategic cooperation agreements on industry-academia-research with Chengdu University of Technology and University of Electronic Science and Technology of China, and jointly inaugurated a particle accelerator laboratory.